Log in

NASDAQ:CUECue Biopharma Stock Price, Forecast & News

+0.45 (+1.65 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $27.68
50-Day Range
MA: $24.31
52-Week Range
Now: $27.68
Volume576,680 shs
Average Volume317,365 shs
Market Capitalization$786.67 million
P/E RatioN/A
Dividend YieldN/A
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.82 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CUE



Sales & Book Value

Annual Sales$3.46 million
Book Value$2.37 per share


Net Income$-36,700,000.00
Net Margins-959.08%


Market Cap$786.67 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

How has Cue Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Cue Biopharma's stock was trading at $15.71 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CUE shares have increased by 76.2% and is now trading at $27.68. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cue Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cue Biopharma.

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cue Biopharma.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) announced its earnings results on Tuesday, May, 19th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.15. Cue Biopharma had a negative return on equity of 103.99% and a negative net margin of 959.08%. View Cue Biopharma's earnings history.

What price target have analysts set for CUE?

5 brokerages have issued twelve-month price targets for Cue Biopharma's stock. Their forecasts range from $13.00 to $33.00. On average, they anticipate Cue Biopharma's share price to reach $27.60 in the next year. This suggests that the stock has a possible downside of 0.3%. View analysts' price targets for Cue Biopharma.

Has Cue Biopharma been receiving favorable news coverage?

Media coverage about CUE stock has been trending negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cue Biopharma earned a news impact score of -2.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCue Biopharma.

Who are some of Cue Biopharma's key competitors?

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), Gilead Sciences (GILD), NVIDIA (NVDA), Opko Health (OPK), Canopy Growth (CGC), General Electric (GE), Inovio Pharmaceuticals (INO), KeyCorp (KEY), Novavax (NVAX) and Verizon Communications (VZ).

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the following people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 58)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 62)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 43)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 46)
  • Dr. Steven C. Almo, Co-Founder and Chairman of Scientific & Clinical Advisory Board (Age 58)

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.00%), Corriente Advisors LLC (2.89%), Prosight Management LP (1.94%), State Street Corp (1.31%), Geode Capital Management LLC (1.09%) and Precept Management LLC (0.74%). Company insiders that own Cue Biopharma stock include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kerri-Ann Millar. View institutional ownership trends for Cue Biopharma.

Which major investors are selling Cue Biopharma stock?

CUE stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, BlackRock Inc., Nuveen Asset Management LLC, Morgan Stanley, UBS Group AG, Invesco Ltd., Voss Capital LLC, and Russell Investments Group Ltd.. View insider buying and selling activity for Cue Biopharma.

Which major investors are buying Cue Biopharma stock?

CUE stock was purchased by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Prosight Management LP, Ghost Tree Capital LLC, Federated Hermes Inc., Geode Capital Management LLC, Private Advisors LLC, Precept Management LLC, and State Street Corp. Company insiders that have bought Cue Biopharma stock in the last two years include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri, and Kerri-Ann Millar. View insider buying and selling activity for Cue Biopharma.

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $27.68.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $786.67 million and generates $3.46 million in revenue each year. The company earns $-36,700,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. Cue Biopharma employs 46 workers across the globe.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is www.cuebiopharma.com.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-949-2680 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.